UBS Maintains Neutral on Chemours, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Joshua Spector maintains a Neutral rating on Chemours (NYSE:CC) and raises the price target from $21 to $28.
April 02, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Joshua Spector maintains a Neutral rating on Chemours and raises the price target from $21 to $28.
The increase in price target from $21 to $28 by a reputable analyst suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term price rise.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100